OMEICOS Therapeutics
Simon’s career began in R&D before gaining over 20 years’ experience in senior commercial and business roles in AstraZeneca, Novartis AG and biotech. Following his last role as Head of Strategic Marketing for Biologics at Novartis, he became CBO of Creabilis Ltd leading commercial, corporate and business development ultimately negotiating its sale to Sienna Biopharmaceuticals with its subsequent IPO on NASDAQ. He is a co-founder of a biotech emerging from the Basel incubator initiative. Dr Russell studied Chemistry at the University of Oxford and received a PhD from Southampton University.
This person is not in any offices
OMEICOS Therapeutics
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.